FDA-Approved Drug Shows Promise in Boosting Immunotherapy for Rare Liver Cancer

Scientists at the University of Washington have discovered that a drug already approved by the U.S. Food and Drug Administration could help boost the efficacy of immunotherapy against a rare type of liver cancer that has previously been unresponsive to checkpoint inhibitors. The study, which focused on fibrolamellar carcinoma, a rare form of liver cancer that primarily affects young adults, suggests that combining this existing drug with immunotherapy may overcome treatment resistance.

Checkpoint inhibition therapy, a cornerstone of modern cancer immunotherapy, works by blocking proteins that prevent the immune system from attacking cancer cells. However, many tumors, including fibrolamellar carcinoma, have shown little to no response to these therapies. The University of Washington team identified a mechanism by which the FDA-approved drug could sensitize cancer cells to checkpoint inhibitors, potentially opening a new treatment avenue for patients with limited options.

While this study specifically targeted fibrolamellar carcinoma, the implications could extend to other cancers that are resistant to immunotherapy. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also dedicating unprecedented research efforts to tackle various cancer types, reflecting a broader push to improve immunotherapy outcomes.

The findings come at a critical time, as liver cancer incidence continues to rise globally, and treatment options for rare subtypes remain scarce. Fibrolamellar carcinoma, which accounts for less than 1% of all liver cancers, often affects adolescents and young adults without underlying liver disease, making the search for effective therapies particularly urgent.

According to the researchers, the next steps involve clinical trials to confirm the combination therapy’s safety and efficacy in patients. If successful, this approach could rapidly become available since the drug is already FDA-approved for other indications, potentially bypassing lengthy regulatory hurdles.

For more information on the latest developments in biotechnology and biomedical sciences, visit BioMedWire, a specialized communications platform that delivers breaking news and insights into the life sciences sector. BioMedWire is part of the Dynamic Brand Portfolio within IBN, which provides a range of services including press release enhancement and social media distribution.

This discovery underscores the importance of repurposing existing drugs to address unmet medical needs, offering hope to patients with rare cancers that have historically been overlooked.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is FDA-Approved Drug Shows Promise in Boosting Immunotherapy for Rare Liver Cancer.

The post FDA-Approved Drug Shows Promise in Boosting Immunotherapy for Rare Liver Cancer appeared first on citybuzz.